SCHEMBL3255128

SCHEMBL3255128

C=C(C)c1cc2ncc(CO)c(N)n2n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.35
RAB9A P51151 6/20 0.35
SMN1; SMN2 Q16637 5/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
TP53 P04637 1/20 0.35
HPGD P15428 1/20 0.35
ALDH1A1 P00352 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
STAT1 P42224 1/20 0.32
NPSR1 Q6W5P4 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
PKM P14618 1/20 0.30
POLB P06746 1/20 0.30
GAA P10253 1/20 0.30
MAPT P10636 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
CYP1A2 P05177 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL235020 0.79 NPC1 (0.54) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL234598 0.78 POLB (0.41) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL238744 0.77 NPC1 (0.36) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL3253086 0.76 PKM (0.32) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL3262344 0.73 NPC1 (0.61) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL2755214 0.72 NPC1 (0.61) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL239025 0.71 FYN (0.38) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL236328 0.70 NPC1 (0.52) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL235072 0.70 NPC1 (0.43) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL237831 0.69 RAB9A (0.67) NPC1RAB9ASMN1; SMN2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 NPC1 1127/4885RAB9A 778/4885SMN1; SMN2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.